| Chemical Properties | Back Directory | [Boiling point ]
624.2±55.0 °C(Predicted) | [density ]
1.319±0.06 g/cm3(Predicted) | [solubility ]
DMSO:62.5(Max Conc. mg/mL);175.35(Max Conc. mM) | [form ]
Solid | [pka]
5.80±0.10(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Description]
DCZ0415 is a novel inhibitor of TRIP13, suppressing multiple myeloma progression. | [Uses]
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1]. | [in vivo]
DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice[1]. | Animal Model: | Nude mice (6-weeks-old) with H929 775 cells[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; every day for 14 days | | Result: | Significantly reduced the growth of MM cells-induced tumors.
|
| [target]
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. | [IC 50]
NF-κB | [References]
[1] Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. DOI:10.1158/0008-5472.CAN-18-3987 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|